ABOVE: Merck research facility in San Francisco © ISTOCK.COM, JASONDOIY
Update (December 23): The US Food and Drug Administration today issued an emergency use authorization for Merck’s oral antiviral drug molnupiravir for non-severe COVID-19 disease cases in high-risk adults when no alternative treatments are available.
Update (November 29): Results of Merck's study of its molnupiravir pill show lower efficacy in reducing hospitalization risk than previously reported by the company, important considerations for the FDA advisory panel meeting this week on the drug's approval, according to STAT.
Update (November 4): The UK’s Medicines and Healthcare products Regulatory Agency announced today it has approved molnupiravir, making the country the first in the world to green light the pill.
Update (October 27): Merck has granted a license to more than 100 low- and middle-income countries to manufacture and sell its molnupiravir pill in a deal with the UN Medicines Patent Pool to increase ...
